Clinical Trials
30 trialsSHR-2554
China Medical University, China
Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping
China Medical University, China
Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach
Peking University
PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer
Peking University Third Hospital
Neoadjuvant Immunotherapy for Resectable Gastric Cancer
Qilu Hospital of Shandong University
A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital of Xiamen University
RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer
The First Affiliated Hospital with Nanjing Medical University
A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer
Jiangsu HengRui Medicine Co., Ltd.
Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer
Tianjin Medical University Cancer Institute and Hospital
Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Peking University
Chemotherapy Combined With Apatinib and PD-1 Antibody
Tianjin Medical University Cancer Institute and Hospital
A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer
Affiliated Hospital of Qinghai University
Apatinib for the Elderly Advanced Gastric Cancer
Affiliated Hospital of Qinghai University
Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer
Fudan University
PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma
China Medical University, China
A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer
Nanfang Hospital, Southern Medical University
The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer
Zhongnan Hospital
Efficacy and Safety of Apatinib Combined With S-1 for Patients With Advance Gastric Cancer
Beijing Friendship Hospital
Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer
Beijing Friendship Hospital
Apatinib Plus XELOX as Neoadjuvant Therapy in Locally Advanced Gastric Cancer
Shanghai Zhongshan Hospital
Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer
Fujian Cancer Hospital
Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301)
Chinese PLA General Hospital
The Study of Conversion Surgery for Apatinib in Combination With SOX for Patients With Unresectable Gastric Cancer
Chinese PLA General Hospital
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
The First Affiliated Hospital of Bengbu Medical University
A Study of Apatinib Combined With S1 in Patients With Advanced Gastric Cancer
Beijing Friendship Hospital
Apatinib Combined With Paclitaxol as Second Line Therapy for Advanced Gastric Cancer.
Sun Yat-sen University
Study of Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in Unresectable Gastric Cancer
The First Affiliated Hospital of Zhejiang Chinese Medical University
The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer
The First People's Hospital of Changzhou
Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric Cancer
Qingdao Municipal Hospital